[Long-term treatment of circulatory disturbances of the retina and optic (author's transl)].
Forty-six patients with in most cases severe vascular degenerative retinochoroidal circulatory disturbances or with glaucomatous visual field defects were treated with rökan dragées (160 mg/day for four weeks, then 120 mg/day). The following were checked at monthly intervals to determine the degree of success of the treatment: visual acuity, visual field, funduscopy, pulse rate and blood pressure, sometimes including intraocular pressure, fluorescence angiography and ODG. The results of the treatment are reported and discussed with regard to the largely bad prognosis of these serious disorders.
D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D020441:Ginkgo biloba; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy; D000096983:Ginkgo Extract
D005419:Flavonoids; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract
Langzeitbehandlung mit rökan bei Durchblutungsstörungen von Netzhaut und Sehnerv.